Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay
US-9216180-B2 · Dec 22, 2015 · US
Composition containing lignan compound as active ingredient for preventing or treating cancer
US9820963B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9820963-B2 |
| Application number | US-201315022546-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 8, 2013 |
| Priority date | Sep 16, 2013 |
| Publication date | Nov 21, 2017 |
| Grant date | Nov 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating lung cancer, comprising administering a pharmaceutical composition comprising a compound extracted from Magnoliae Flos of Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient: 2. The method of claim 1 , wherein the composition comprising the compound extracted from Magnoliae Flos further comprises one or more compounds selected from the group consisting of dimethylpinoresinol, dimethylliroresinol, epieudesmin, epimagnolin, demethoxyaschantin, aschantin, and fargesin. 3. The method of claim 1 , wherein the compound of Chemical Formula 1 in the pharmaceutical composition is in a concentration range from 1 μM to 100 μM. 4. The method of claim 1 , wherein the composition comprising the compound extracted from Magnoliae Flos treats lung cancer by controlling extracellular signal-regulated kinase (ERK) activity and inhibiting a proliferation of tumor cells. 5. A method for ameliorating lung cancer, comprising administering a health functional food composition comprising a compound extracted from Magnoliae Flos of Chemical Formula 1 or a sitologically acceptable salt thereof as an active ingredient: 6. A method for treating lung cancer, comprising administering a pharmaceutical composition comprising a chloroform fraction of Magnoliae Flos containing magnolin as an active ingredient. 7. The method of claim 6 , wherein the composition further comprises one or more compounds selected from the group consisting of dimethylpinoresinol, dimethylliroresinol, epieudesmin, epimagnolin, demethoxyaschantin, aschantin, and fargesin. 8. The method of claim 6 , wherein the Magnoliae Flos chloroform fraction containing magnolin of the pharmaceutical composition is in a concentration range from 2 μg/mL to 250 μg/mL. 9. A method for ameliorating lung cancer, comprising administering a health functional food composition comprising a chloroform fraction of Magnoliae Flos containing magnolin as an active ingredient.
Assignees
Inventors
Classifications
- A61K31/34Primary
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide · CPC title
- A61K31/36Primary
Compounds containing methylenedioxyphenyl groups, e.g. sesamin · CPC title
Magnolia · CPC title
Orchidaceae (Orchid family) · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9820963B2 cover?
- The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer includin…
- Who is the assignee on this patent?
- Korea Res Inst Bioscience & Biotechnology
- What technology area does this patent fall under?
- Primary CPC classification A61K31/34. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).